The LAM Foundation

Financial Statements December 31, 2022 and 2021, and Independent Auditors' Report

THE LAM FOUNDATION December 31, 2022 and 2021

Contents

	Page(s)
Independent Auditors' Report	1 - 2
Financial Statements:	
Statements of Financial Position	3
Statements of Activities	4 - 5
Statements of Functional Expenses	6 - 7
Statements of Cash Flows	8
Notes to Financial Statements	9 - 16



CINCINNATI OFFICE 150 E. 4th Street

Cincinnati, OH 45202 Main: 513.241.8313 Fax: 513.241.8303

Independent Auditors' Report

To the Board of Directors
The LAM Foundation
Cincinnati, Ohio

Opinion

We have audited the accompanying financial statements of The LAM Foundation (a nonprofit organization), which comprise the statements of financial position as of December 31, 2022 and 2021, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The LAM Foundation as of December 31, 2022 and 2021, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of The LAM Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about The LAM Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

BARNES DENNIG

Independent Auditors' Report (Continued)

Auditors' Responsibility for the Audit of the Financial Statements (Continued)

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such
 procedures include examining, on a test basis, evidence regarding the amounts and disclosures
 in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of The LAM Foundation's internal control. Accordingly, no such
 opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about The LAM Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

June 7, 2023 Cincinnati. OH

Gunes, Dunig & Co., Std.

Statements of Financial Position December 31, 2022 and 2021

	2022	2021
Assets		
Current assets:		
Cash and cash equivalents	\$ 2,836,260	\$ 3,175,345
Accounts and short term pledges receivable	34,061	5,615
Prepaid expenses and other current assets	29,335	31,864
Total current assets	2,899,656	3,212,824
Other assets:		
Long term pledges receivable, net	3,175	5,500
Property and equipment, net	-	214
Intangibles, net	199	470
Total other assets	3,374	6,184
Total assets	\$ 2,903,030	\$ 3,219,008
Liabilities and Net Assets		
Liabilities		
Current liabilities:		
Accounts payable and refundable advances	\$ 25,356	\$ 10,371
Compensation and related taxes payable	24,086	26,417
Funds held for others	23,322	28,787
Research grants payable	233,568	255,000
Total current liabilities	306,332	320,575
Net Assets		
Without donor restrictions:		
Available for operations	1,413,128	1,812,459
Board designated	895,366	749,697
Invested in property and equipment and intangibles	199	684
Total without donor restrictions	2,308,693	2,562,840
With donor restrictions	288,005	335,593
Total net assets	2,596,698	2,898,433
Total liabilities and net assets	\$ 2,903,030	\$ 3,219,008

Statement of Activities Year Ended December 31, 2022

	Without Donor Restrictions		With Donor Restrictions		Total
Support, revenues and gains					
Support and revenues:					
Honor, memorial, bequests and					
general donations	\$	811,164	\$	-	\$ 811,164
Contributions from special events, net		535,860		-	535,860
Corporate and foundation gifts		60,324		-	60,324
Conference registrations and sponsorships		156,627		-	156,627
Contributed services		42,000		-	42,000
Miscellaneous income		7,698		-	7,698
Net assets released from restrictions		47,588		(47,588)	
Total support, revenues and gains		1,661,261		(47,588)	1,613,673
Expenses					
Research		933,242		_	933,242
Patient services		482,215		_	482,215
Clinical		105,468			105,468
Total program expenses		1,520,925		-	1,520,925
Management and general		169,087		-	169,087
Fundraising		225,396			225,396
Total expenses		1,915,408			1,915,408
Change in net assets		(254,147)		(47,588)	(301,735)
Net assets, beginning of year	2,562,840		335,593		2,898,433
Net assets, end of year	\$	2,308,693	\$	288,005	\$ 2,596,698

Statement of Activities Year Ended December 31, 2021

	Without Donor Restrictions	With Donor Restrictions	Total
Support, revenues and gains			
Support and revenues:			
Honor, memorial, bequests and			
general donations	\$ 1,440,682	\$ 2,400	\$ 1,443,082
Contributions from special events, net	658,387	-	658,387
Corporate and foundation gifts	106,340	-	106,340
Contributed services	43,378	-	43,378
Miscellaneous income	1,776	-	1,776
Net assets released from restrictions	20,717	(20,717)	
Total support, revenues and gains	2,271,280	(18,317)	2,252,963
Expenses			
Research	720,251	-	720,251
Patient services	246,522	-	246,522
Clinical	84,164		84,164
Total program expenses	1,050,937	-	1,050,937
Management and general	158,734	-	158,734
Fundraising	180,222		180,222
Total expenses	1,389,893		1,389,893
Change in net assets	881,387	(18,317)	863,070
Net assets, beginning of year	1,681,453	353,910	2,035,363
Net assets, end of year	\$ 2,562,840	\$ 335,593	\$ 2,898,433

Statement of Functional Expenses Year Ended December 31, 2022

	Program Services						Supporting Services				
				Patient				nagement			
	R	Research S		Services		Clinical	and General		<u>Fu</u>	ndraising	 Total
Compensation	\$	107,271	\$	212,520	\$	75,778	\$	90,833	\$	116,675	\$ 603,077
Research grants and awards		431,511		-		-		-		-	431,511
LAMposium conference		165,642		181,722		5,219		212		9,502	362,297
Professional services		87,673		46,468		9,746		55,315		48,918	248,120
Clinical research support		52,969	944			-		-		-	53,913
Contributed services		42,000		-		-		-		-	42,000
Publicity and communications		17,479		17,150		12		26		3,022	37,689
Occupancy costs		7,536		10,424		2,461		5,697		9,041	35,159
Bank, credit card, and filing fees (refunds)		(1,500)		-		-		2,694		18,714	19,908
Conferences		10,510		183		5,938		-		-	16,631
Printing and publications		1,568		1,725		-		-		12,932	16,225
Travel		5,018		1,453		-		5,011		1,725	13,207
Miscellaneous		2,440		2,433		-		3,974		-	8,847
Telephone		1,361		2,430		3,774		383		450	8,398
Office expenses		819		1,993		2,245		761		536	6,354
Shipping and postage		323		513		50		1,682		3,558	6,126
Meetings		159		123		7		1,841		121	2,251
Equipment lease		463		1,084		238		173		202	2,160
LAM patient network support		-		1,050		-		-		-	1,050
Depreciation and amortization								485			485
Total expenses	\$	933,242	\$	482,215	\$	105,468	\$	169,087	\$	225,396	\$ 1,915,408

Statement of Functional Expenses Year Ended December 31, 2021

	Program Services					Supporting Services						
	Patient Research Services Clinica		Clinical	Management and General Fundraising				Total				
Compensation	\$	132,548	\$	159,907	\$	69,527	\$	93,833	\$	85,213	\$	541,028
Research grants and awards		457,700		-		-		-		-		457,700
LAMposium conference		3,867		3,839		-		-		-		7,706
Professional services		37,248		38,478		7,765		50,902		52,016		186,409
Clinical research support		15,935		-		-		-		-		15,935
Contributed services		43,378		-		-		-		-		43,378
Publicity and communications		12,950		15,160		2,210		-		-		30,320
Occupancy costs		7,503		10,378		2,450		5,672		9,001		35,004
Bank, credit card, and filing fees		-		-		-		1,838		17,949		19,787
Conferences		1,000		60		-		-		-		1,060
Printing and publications		3,900		4,045		-		-		10,186		18,131
Miscellaneous		1,318		1,243		75		2,708		170		5,514
Telephone		910		5,447		1,079		350		407		8,193
Office expenses		797		5,466		436		953		599		8,251
Shipping and postage		476		599		368		1,681		4,448		7,572
Meetings		258		251		16		141		31		697
Equipment lease		463		1,084		238		173		202		2,160
LAM patient network support		-		565		-		-		-		565
Depreciation and amortization				<u> </u>		<u> </u>		483				483
Total expenses	\$	720,251	\$	246,522	\$	84,164	\$	158,734	\$	180,222	\$	1,389,893

Statements of Cash Flows Years Ended December 31, 2022 and 2021

	2022			2021	
Cash flows from operating activities			_		
Change in net assets	\$	(301,735)		\$	863,070
Adjustments to reconcile change in net assets to					
net cash from operating activities:					
Depreciation and amortization		485			483
Changes in:					
Accounts and pledges receivable		(26,121)			19,706
Prepaid expenses and other current assets		2,529			2,235
Accounts payable and refundable advances		14,985			(6,184)
Compensation and related taxes payable		(2,331)			2,856
Funds held for others		(5,465)			(3,932)
Research grants payable		(21,432)	_		6,038
Net cash provided by (used in) operating activities		(339,085)	_		884,272
Cash flows from investing activities					
Redemptions of certificates of deposit			_		5,076
Net cash provided by investing activities			_		5,076
Net change in cash and cash equivalents		(339,085)			889,348
Cash and cash equivalents, beginning of year		3,175,345	_		2,285,997
Cash and cash equivalents, end of year	\$	2,836,260	_	\$	3,175,345

Notes to Financial Statements

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of The LAM Foundation (the Foundation) is presented to assist in understanding the Foundation's financial statements. The financial statements and notes are representations of the Foundation's management who is responsible for their integrity and objectivity.

Nature of Operations

The Foundation is an Ohio non-profit entity incorporated in 1995 urgently seeking safe and effective treatments and ultimately a cure for Lymphangioleiomyomatosis (LAM). LAM is a progressive and frequently fatal lung disease that affects primarily women. The Foundation believes its goals will be achieved through patient advocacy, the funding of promising research and advancement of clinical expertise in the treatment of LAM through a global network of LAM clinics. The Foundation is dedicated to serving the scientific, medical and patient communities by offering information, resources and a worldwide network of hope and support. The Foundation is governed by a Board of Trustees and obtains significant funding from contributions and fundraising activities.

Basis of Presentation

The financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles (GAAP). The Foundation is required to report information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions, which are available for use in general operations and not subject to donor restrictions; and net assets with donor restrictions which are either temporary in nature, such as those that will be met by the passage of time or other events specified by the donor, or are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity.

Cash and Cash Equivalents

The Foundation considers all liquid investments with original maturities of three months or less to be cash equivalents. At December 31, 2022 and 2021, cash equivalents consisted primarily of money market deposit accounts and certificates of deposits. The Foundation maintains its cash in bank deposit accounts which, at times, exceed federally insured limits. The Foundation has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Pledges and Accounts Receivable

Pledges and accounts receivable are due from various donors and the general public. An allowance for bad debts is reported when necessary to provide for estimated uncollectible accounts. The Foundation has not experienced any significant losses on its receivables and believes it is not exposed to significant credit risk on its receivables. As of December 31, 2022 and 2021, management considers all pledges and accounts receivable collectable, thus, no allowance is recorded.

Notes to Financial Statements (Continued)

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Property and Equipment

Property and equipment are recorded at cost at the date of acquisition or at estimated fair value at date of gift, if donated. The Foundation's policy is to capitalize asset purchases that exceed \$500. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets, which range from three to six years.

When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is recognized in income or expense for the period. The cost of maintenance and repairs is expensed as incurred while significant improvements are capitalized.

Intangible Assets

Intangible assets are recorded at cost at the date of acquisition and amortized over their estimated useful lives. The Foundation's policy is to capitalize intangible asset purchases that exceed \$500. As of December 31, 2022 and 2021, the Foundation had \$6,531 in trademarks with the United States, Europe and Canada. Amortization expense for the years ended December 31, 2022 and 2021 was \$271 each year. Accumulated amortization as of December 31, 2022 and 2021 was \$6,332 and \$6,061, respectively.

Contributions

The Foundation records gifts of cash and other assets at their estimated fair value as of the date of contribution. Such donations are recorded as support without donor restrictions unless explicit donor stipulations specify how the assets are to be used. A gift that is originally restricted by the donor for which the restriction is met in the same year that the gift is received is recorded as revenue without donor restrictions.

Gifts of cash or other assets that must be used to acquire long-lived assets are reported as support with donor restrictions. Absent explicit donor stipulations about how long these long-lived assets must be maintained, the Foundation reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service.

Unconditional promises to give expected to be collected within one year are reported at their net realizable value. Unconditional gifts expected to be collected in future years are reported at the present value of estimated cash flows. The resulting discount is amortized and reported as contribution revenue. Conditional promises to give are recognized as revenues when the conditions on which they depend are substantially met.

Contributed Services

The Foundation records contributed services as revenues in the period received only when the services rendered create or enhance non-financial assets or require specialized skills, are provided by individuals possessing those skills, and would typically be purchased if not provided by donation. Additionally, not included in the accompanying financial statements is the value of a substantial number of volunteers (including Board members) that have donated significant amounts of time for programming and fundraising activities.

Notes to Financial Statements (Continued)

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Leases

The Foundation determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities on the statement of financial position. The operating lease ROU asset and operating lease liabilities are recognized as the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Foundation uses the risk-free rate at the commencement date of the leases in determining the present value of future payments. The operating ROU asset also is adjusted for any lease payments made and excludes lease incentives and initial direct costs incurred. The Foundation's lease terms may include options to extend or terminate the lease at certain dates, typically at the Foundation's discretion. Lease expense for minimum lease payments is recognized on a straight-line basis over the term of the arrangement.

The Foundation made an accounting policy election that payments under agreements with an initial term of 12 months or less will not be included on the statement of financial position but will be recognized in the statements of activities on a straight-line basis over the term of the agreement.

Functional Allocation of Expenses

The costs of supporting the various programs and other activities have been summarized on a functional basis in the statement of functional expenses. Accordingly, certain costs have been allocated among the programs and supporting services. Such allocations are determined by management on an equitable basis. The most significant allocations were salaries and other employee costs which were allocated based upon estimates of time and effort spent by the Foundation's personnel on each functional area. Other expenses are charged based on specific identification when feasible or are otherwise allocated using rational and reasonable cost allocation methodologies.

Use of Estimates

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. Accordingly, actual results could differ from those estimates.

Income Tax Status

The Foundation is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code and a similar provision of Ohio law. However, the Foundation is subject to federal income tax on any unrelated business taxable income.

The Foundation's IRS Form 990 is subject to review and examination by federal and state authorities. The Foundation believes it has appropriate support for any tax positions taken, and therefore, does not have any uncertain income tax positions that are material to the financial statements.

Notes to Financial Statements (Continued)

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Effect of Adopting New Accounting Standards

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 842, *Leases* to increase transparency and comparability among organizations by requiring the recognition of right-of-use (ROU) assets and lease liabilities on the balance sheet. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Organization adopted the standard effective January 1, 2022. The standard did not result in a material change to the financial statements.

In September 2020, the FASB issued Accounting Standard Update (ASU) 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosure by Not-for-Profit Entities for Contributed Nonfinancial Assets* to increase transparency of contributed nonfinancial assets through enhancements to presentation and disclosure. These include separate presentation in the statement of activities, disaggregation by type, policy and qualitative information about monetization and utilization, description of valuation techniques and inputs used to arrive at a fair value measure, and donor-imposed restrictions associated with the contributed nonfinancial assets. The Organization adopted the standard effective January 1, 2022, applied retrospectively.

Subsequent Events

In preparing its financial statements, the Foundation has evaluated events subsequent to the statement of financial position date through June 7, 2023, which is the date the financial statements were available to be issued.

NOTE 2 LIQUIDITY AND AVAILABILITY

The Foundation strives to maintain liquid assets sufficient to cover six months of general expenditures. Financial assets in excess of daily cash requirements and grant funding are invested in certificates of deposit and money market funds.

The following table reflects the Foundation's financial assets as of December 31, 2022 and 2021, reduced by amounts that are not available to meet general expenditures within one year of the statement of financial position date because of contractual restrictions or internal board designations. Amounts not available include board designated net assets that are intended to fund special board initiatives related to research and not considered in the annual operating budget. In the event the need arises to utilize the board designated funds for liquidity purposes, the reserves could be drawn upon through board resolution. Amounts not available to meet general expenditures within one year also may include net assets with donor restrictions. Net assets with donor restrictions were \$288,055 and \$335,593 at December 31, 2022 and 2021, respectively.

Notes to Financial Statements (Continued)

NOTE 2 LIQUIDITY AND AVAILABILITY (CONTINUED)

	2022		2021
Cash and cash equivalents Accounts and short term pledges receivable Long term pledges receivable, net	\$ 2,836,260 34,061 3,175	\$	3,175,345 5,615 5,500
Total financial assets	2,873,496		3,186,460
Less those unavailable for general expenditures within one year:			
Long term pledges receivable, net	(3,175)		(5,500)
Funds held for others	(23,322)		(28,787)
Cash to be used for grants payable	(233,568)		(255,000)
Board designated net assets	(895,366)		(749,697)
Net assets with donor restrictions	(288,005)		(335,593)
Financial assets available to meet cash needs for general expenditures within one year	\$ 1,430,060	\$	1,811,883

NOTE 3 PLEDGES RECEIVABLE

Pledges receivable at December 31 consisted of the following:

	 2022	 2021
Due within one year Due in one to five years	\$ 28,700 3,175	\$ 2,900 5,500
	\$ 31,875	\$ 8,400

No amounts have been recorded as an allowance for doubtful accounts as the Foundation considers all pledges to be fully collectible. Additionally, no discount on pledges has been recognized as of December 31, 2022 and 2021, as the amount would be considered immaterial.

NOTE 4 PROPERTY AND EQUIPMENT

Property and equipment at December 31 are as follows:

	2022	 2021
Equipment Less accumulated depreciation	\$ 39,269 (39,269)	\$ 39,269 (39,055)
	\$ _	\$ 214

Depreciation expense for both years ended December 31, 2022 and 2021 was \$214.

Notes to Financial Statements (Continued)

NOTE 5 FUNDS HELD FOR OTHERS

The Foundation has an agreement with Cincinnati Children's Hospital Medical Center (CCHMC) to administer the Rare Lung Disease Consortium (RLDC) and the multi-site clinical studies conducted within the RLDC. The grant includes funds awarded to the Foundation for administrative support and funds to be passed through to the approved clinical research institutions as directed by the study chairs. Funds held for others, and to be passed through to the approved clinical research institutions, included in the statement of financial position as of December 31, 2022 and 2021 were \$23,322 and \$28,787, respectively.

NOTE 6 RESEARCH GRANTS PAYABLE

The Foundation provides six grant award types: Career Development Awards, Established Investigator Awards, Pilot Project Awards, Designated Awards, Special Project Awards and Bridge Funding Awards. Career Development Awards provide support for postdoctoral research fellows who are starting their research careers and are working in the laboratories of established researchers or conducting research with the mentorship of established researchers. Established Investigator Awards provide a maximum of three years of salary support for a technician. Pilot Project Awards provide seed monies to pursue new research directions. A Designated Award supports work in which fundraisers and donors work with the Foundation to support specific research projects or awareness programs, chosen from a slate of pre-peer reviewed and Board approved proposals. Special Project Awards fund projects that do not fall into one of the above three categories and Bridge Funding Awards provide interim funding until anticipated funding from other sources is awarded.

The Foundation has the right to withdraw or modify the amount awarded based on review of each project's results. Project results are reviewed at least annually. Therefore, the Foundation accrues a payable for the approved award payments for the succeeding 12 months with the remainder representing a contingent liability. Grants payable were \$233,568 and \$255,000 at December 31, 2022 and 2021, respectively.

The additional, yet contingent amounts were approximately \$610,432 and \$665,500 at December 31, 2022 and 2021, respectively. The Foundation's Board of Directors has, however, designated these amounts of its net assets without donor restrictions for the funding of these contingent fellowships.

NOTE 7 RETIREMENT PLAN

The Foundation established a simple IRA plan covering substantially all employees. Employees may contribute a portion of their compensation not to exceed the maximum allowed by the Internal Revenue Service. The Foundation contributed a total of \$14,774 and \$13,426 in 2022 and 2021 respectively, to the plan.

Notes to Financial Statements (Continued)

NOTE 8 BOARD DESIGNATED NET ASSETS

Board designated net assets as of December 31 consisted of the following:

	2022	2021		
Research grants payable in one year	\$ 276,182	\$	190,500	
Research grants payable after one year	334,250		475,000	
Endowed Chair	200,000		-	
Other research, TRAIL, Single Cell analysis	43,562		72,825	
Shellie Owens First Time Travel Fund	30,000		-	
2020 funding redirected	11,372		11,372	
	\$ 895,366	\$	749,697	

NOTE 9 NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions as of December 31 include donor restricted support for a future clinical drug trial, contributions to fund patient travel to the Foundation's annual conference and their first visit to the National Institutes of Health, and future support of the Foundation's research program services. Net assets with donor restrictions were available for the following purposes:

		2021		
MILED trial	\$	211,861	\$	235,861
Research		50,000		50,000
LAM Family Network		25,351		45,889
Helen Green travel grant		793		1,443
LAMposium in Your Living Room sponsorships		-		2,400
	\$	288,005	\$	335,593

NOTE 10 CONTRIBUTED SERVICES

Contributed services consisted of the following at December 31:

	2022		2021	
LAM research and consultation services MIDAS research services	\$	42,000 -	\$	42,000 1,378
	\$	42,000	\$	43,378

LAM research and consultation services consist of professional services provided by a Scientific Director. As the Scientific Director does not track his hours donated to the Foundation, the Foundation values his services based on an estimated fair value of \$3,500 per month. In 2021, the Foundation also received professional services to support MIDAS research from a Clinical Trial Consultant. The Foundation valued this at an hourly rate provided by the Clinical Trial Consultant of \$53 for 26 hours of donated time. The Foundation uses these professional services for research purposes and all donated services are without donor restrictions.

Notes to Financial Statements (Continued)

NOTE 11 LEASES

The Foundation leases office space under a short-term operating lease that is set to expire on May 31, 2023. Short-term lease expense for this lease included in occupancy costs for the years ended December 31, 2022 and 2021 was \$31,254 and \$31,017, respectively.

NOTE 12 COMMITMENTS

During 2019, the Foundation made a commitment to the University of Cincinnati Foundation and the University of Cincinnati College of Medicine to establish The LAM Foundation Endowed Chair for LAM Research ("Endowed Chair"). During 2020, the Endowed Chair was established to support the work of an associate professor of clinical medicine who may also serve as a resource for advice, advocacy and leadership at the Foundation.

In February 2022, the Foundation's Board of Directors voted to formalize a prior commitment to fund an additional \$200,000 to the Endowed Chair.